Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients - Takeaways - MDSpire

Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients

  • By

  • H. Habibullah

  • M. Alotaibi

  • H. Almarzouki

  • Z. Mulla

  • M. Elbaiomy

  • R. Alahmadi

  • A. Ahmed

  • Y. Bahadur

  • R. Ujaimi

  • E. Senan

  • M. Attar

  • A. Bamakhramah

  • H. Altoukhi

  • H. Muamenah

  • O. Iskanderani

  • R. Garout

  • J. Alturkistani

  • H. Hijazi

  • Z. Jastaniah

  • June 10, 2026

  • 0 min

Share

  • 1

    The FAST-Forward trial showed 26 Gy in five fractions is non-inferior to 40 Gy in 15 fractions for breast cancer treatment.

  • 2

    This study analyzed 100 breast cancer patients treated with 26 Gy in five fractions in Saudi Arabia from June 2020 to June 2023.

  • 3

    Breast skin dermatitis was the most common toxicity, affecting 82.35% of patients, with 5% experiencing Grade III dermatitis.

  • 4

    Larger breast volume, higher BMI, and increased V105% and V107% values were associated with greater toxicity in patients.

  • 5

    The study provides insights into optimizing dosimetric factors to potentially reduce adverse effects in breast cancer radiotherapy.

Original Source(s)

Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients

  • by H. Habibullah, M. Alotaibi, H. Almarzouki, Z. Mulla, M. Elbaiomy, R. Alahmadi, A. Ahmed, Y. Bahadur, R. Ujaimi, E. Senan, M. Attar, A. Bamakhramah, H. Altoukhi, H. Muamenah, O. Iskanderani, R. Garout, J. Alturkistani, H. Hijazi, Z. Jastaniah

  • June 10, 2026

Related Content

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

The impact of statin therapy on the prognosis of hormone receptor-positive breast cancer: a systematic review and meta-analysis

Correction: Time-dependent diffusion MRI for noninvasive molecular subtype differentiation and biological correlation in breast cancer: emphasizing the emerging three-tier HER2 classification